We identified seven patients (inflammatory myofibroblastic tumors, n = 3; ALK-positive histiocytosis, n = 1; histiocytic sarcoma, n = 1; osteosarcoma, n = 1; and parotid adenocarcinoma, n = 1), with a median age of 17 years. Two rare ALK fusions, namely, CTNNA1-ALK and ITSN2-ALK, were identified. As initial ALK-TKI therapy, five patients received alectinib and two received crizotinib. The objective response rate for the initial ALK-TKI therapy was 85.7% (95% CI, 44 to 97), including two patients who received alectinib and achieved complete response. The median progression-free survival was 8.1 months (range, 1.7 to not estimable). There were no treatment interruptions or dose reductions because of adverse events caused by alectinib. This study highlights the potential benefit of ALK-TKIs, especially alectinib, in patients with ALK-rearranged nonlung solid tumors.
READ ARTICLE
Journal of Clinical Oncology: Precision Oncology DOI:10.1200/PO.20.00383
Authors: Yuki
Takeyasu; Hitomi S. Okuma; Yuki Kojima; Tadaaki Nishikawa; Maki Tanioka; Kazuki Sudo; Tatsunori Shimoi; Emi Noguchi; Ayumu Arakawa; Taisuke Mori; Kuniko Sunami, Takashi Kubo; Takashi Kohno; Yoshida Akihiko; Noboru Yamamoto; and Kan Yonemori